PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2019.03.009
Abstract: Chemotherapy is no longer the only viable option for patients with locally advanced or metastatic urothelial carcinoma. Immunotherapy, as checkpoint inhibition, has received United States Food and Drug Administration approval in the preceding several years,… read more here.
Keywords: line; current clinical; combinations advanced; clinical trials ... See more keywords